Berberine Inhibited the Growth of Thyroid Cancer Cell Lines 8505C and TPC1.
10.3349/ymj.2012.53.2.346
- Author:
Kyoung Sik PARK
1
;
Jong Bin KIM
;
Jaeman BAE
;
Seo Young PARK
;
Hyeon Gun JEE
;
Kyu Eun LEE
;
Yeo Kyu YOUN
Author Information
1. Department of Surgery, Konkuk University School of Medicine, Seoul, Korea.
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Berberine;
anticancer-drug;
thyroid cancer;
growth
- MeSH:
Antineoplastic Agents/*pharmacology;
Apoptosis/drug effects;
Berberine/*pharmacology;
Cell Cycle/drug effects;
Cell Line, Tumor;
Cell Proliferation/drug effects;
Humans;
Thyroid Neoplasms/*metabolism
- From:Yonsei Medical Journal
2012;53(2):346-351
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Thyroid cancer is the most common malignancy in Korean females and can be treated with good prognosis. However, drugs to treat aggressive types of thyroid cancer such as poorly differentiated or anaplastic thyroid cancer have not yet been established. To that end, we analyzed the effects of berberine on human thyroid cancer cell lines to determine whether this compound is useful in the treatment of aggressive thyroid cancer. MATERIALS AND METHODS: The two thyroid cancer cell lines 8505C and TPC1, under adherent culture conditions, were treated with berberine and analyzed for changes in cell growth, cell cycle duration, and degree of apoptosis. RESULTS: Following berberine treatment, both cell lines showed a dose-dependent reduction in growth rate. 8505C cells showed significantly increased levels of apoptosis following berberine treatment, whereas TPC1 cells showed cell cycle arrest at the G0/G1 phase. Immunobloting of p-27 expression following berberine treatment showed that berberine induced a little up-regulation of p-27 in 8505c cells but relatively high up-regulation of p-27 in TPC1 cells. CONCLUSION: These results suggest that berberine treatment of thyroid cancer can inhibit proliferation through apoptosis and/or cell cycle arrest. Thus, berberine may be a novel anticancer drug for the treatment of poorly differentiated or anaplastic thyroid cancer.
